Why BioCryst Pharmaceuticals Stock Sank Today
Shares of BioCryst Pharmaceuticals (NASDAQ: BCRX) took it on the chin Monday, suffering a nearly 7% decline in value. Not for the first time in recent days, the company was socked by an analyst's increasingly dim view of its prospects.
Barclays prognosticator Gena Wang didn't exactly get BioCryst's week off to an encouraging start. Monday morning, she downgraded her recommendation on the stock to equalweight (read: neutral) from the previous overweight (buy). In doing so, she took a big whack to her price target; it's now $13 per share, where formerly it was $22.
Image source: Getty Images.
Source Fool.com
